TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01964040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block
Description: ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia
Study: NCT01135667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: clopidogrel 150 mg once daily for 30 days
Study: NCT03936296

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12 core standard transrectal prostate biopsy
Description: Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
Study: NCT04651270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurroundScope
Description: The study will evaluate standard laparoscopic surgery using the 270Surgical system. The procedure will be performed according to the institution's standard of care, using the SurroundScope for visualization.
Study: NCT01135667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 10 mg
Description: Prasugrel 10 mg once daily for 30 days
Study: NCT01193296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT04517357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib-Apatinib combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib
Description: Fluzoparib monotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib-Apatinib combination
Study: NCT03699475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: Biological: T cells transduced with caspase 9 safety switch

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rivogenlecleucel
Description: Biological: T cells transduced with caspase 9 safety switch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimiducid
Description: administered to inactivate rivogenlecleucel in the event of GVHD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimiducid
Description: administered to inactivate rivogenlecleucel in the event of GVHD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: GVHD prophylaxis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haplo-HSCT
Description: treatment for disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haplo-HSCT
Description: treatment for disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haplo-HSCT
Description: treatment for disease
Study: NCT03243708

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk calculator
Description: Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
Study: NCT06506370

Intervention type: OTHER
Intervention: nonsurgical periodontal treatment
Description: The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.

Intervention type: OTHER
Intervention: nonsurgical periodontal treatment
Description: The patients underwent treatment in accordance with the guidelines of the European Federation of Periodontology (EFP). Initially, patients were informed of their condition, educated on oral hygiene practices, and advised to cease detrimental habits such as smoking. Following this, supragingival cleaning was conducted using ultrasound, with manual subgingival instrumentation utilizing a reduced set of Gracey curettes for pockets exceeding 4 mm with persistent bleeding or greater than 6 mm.
Study: NCT01610375

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone Follow-up
Description: This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
Study: NCT01471431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spontaneous breathing trial
Description: The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia \<100 for \>15 seconds or oxygen saturation by pulse oximetry \<85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met.
Study: NCT01955798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic direct entry Trocar
Description: Laparoscopic direct entry with trocar

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic entry Veress needle
Description: Laparoscopic entry with Veress needle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trocar

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veress needle
Study: NCT00528970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: MOA-728 will be administered per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOA-728
Description: MOA-728 will be administered per the dose and schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Study: NCT01440543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water immersion insertion AND CO2 insufflation
Description: * room temperature water infused by water pump into the colon just to facilitate scope insertion~* CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water immersion insertion
Description: * room temperature water infused by water pump into the colon just to facilitate scope insertion~* standard room air insufflation during colonoscope withdrawal and mucosal inspection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: - CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
Study: NCT03932006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fengshigutong Capsule plus Imrecoxib
Description: Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fengshigutong Capsule
Description: Fengshigutong Capsule 1.2g twice a day,orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imrecoxib
Description: Imrecoxib 0.1g twice a day,orally
Study: NCT04710771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone Lying Position
Description: patient lies on his/ her stomach facing floor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prone Lying Position
Description: patient lies on his/ her stomach facing floor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alternate nostril breathing
Description: patient inspires with one nostril at a time, right or left one by one and expires by mouth.
Study: NCT04671953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Specified dose on specified days
Study: NCT04280770

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 23 PARS PLANA VITRECTOMY
Description: We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 23 PARS PLANA VITRECTOMY
Description: We performed a three-port vitrectomy: one infusion trocar and two instruments trocars. Non-contact wide-angle viewing systems (Resight- Biom) have a viewing field of 60-130° was used. Put 23 needle attached to the automated pump for silicone oil extraction. Strict examination of the retina to detect new breaks or untreated breaks. Closure of the sclerotomies.
Study: NCT01143233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control formula
Description: infants are fed a commercial hydrolyzed formula
Study: NCT01918254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion will be administered as per schedule described in individual arm.
Study: NCT01143233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 1
Description: formula has hydrolysed protein and a different protein content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 2
Description: formula has hydrolysed protein, different protein content and pro- and prebiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention formula 3
Description: formula has hydrolysed protein, different protein content and pro- and prebiotics
Study: NCT01918254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumretuzumab
Description: Lumretuzumab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumretuzumab
Description: Lumretuzumab will be administered as per schedule described in individual arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumretuzumab
Description: Lumretuzumab will be administered as per schedule described in individual arm.
Study: NCT01816503

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
Study: NCT03571945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-spectral Index (BIS QUATRO REF #186-0106)
Description: GA will be monitored and controlled with Bi-spectral index (BIS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: End tidal anaesthesia gas concentration (ETAG)
Description: GA will be monitored and controlled with end-tidal anaesthesia gas concentration
Study: NCT01596556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: both groups will be given nicotine lozenges before a VO2 test and a HTT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: both groups will be given nicotine lozenges before a VO2 test and a HTT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cigarette smoking
Description: the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
Study: NCT00541190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Description: Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Description: Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
Study: NCT03611842

Intervention type: OTHER
Intervention: preservation of mucosal otitis media
Description: Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum

Intervention type: OTHER
Intervention: preservation of mucosal otitis media
Description: Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
Study: NCT03787979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study: NCT02648828

Intervention type: OTHER
Intervention: Clinical deterioration
Description: Patients at risk of clinical deterioration

Intervention type: OTHER
Intervention: Clinical deterioration
Description: Patients at risk of clinical deterioration

Intervention type: OTHER
Intervention: Clinical deterioration
Description: Patients at risk of clinical deterioration
Study: NCT02408432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Undergo mesenchymal stem cell infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Undergo mesenchymal stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell Transplantation
Description: Undergo mesenchymal stem cell infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cell Transplantation
Description: Undergo mesenchymal stem cell infusion
Study: NCT00637143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Oral
Study: NCT01293578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Choice Cards
Description: Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
Study: NCT04662827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmithylethanolamid
Description: PEA 3x/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Palmithylethanolamid
Description: PEA 3x/d

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo 3x/d

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 3x/d
Study: NCT02853799

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients
Description: 1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients
Description: 1. Placement of feeding tube stomach (oral- or naso-gastric tube)~2. Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~3. There will be five blood glucose checks in each data collection period.~4. If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Osmolite 1.2 cal/ml Enteral Feeds
Description: Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Osmolite 1.2 cal/ml Enteral Feeds
Description: Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
Study: NCT02744742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor(G-CSF)
Description: G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
Study: NCT03848156

Intervention type: OTHER
Intervention: biopsy
Description: Biopsy of nasal polyp for RNA sequencing

Intervention type: OTHER
Intervention: biopsy
Description: Biopsy of nasal polyp for RNA sequencing

Intervention type: OTHER
Intervention: biopsy
Description: Biopsy of nasal polyp for RNA sequencing

Intervention type: OTHER
Intervention: biopsy
Description: Biopsy of nasal polyp for RNA sequencing
Study: NCT02761837

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IVR call/text
Description: For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email
Description: Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
Study: NCT02029690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20